Abbott Cuts Kaletra Price In 40 Countries
This article was originally published in PharmAsia News
Executive Summary
Abbott announced April 10 that it would cut the price of its HIV therapy Kaletra (lopinavir/ritonavir) in more than 40 developing countries to around $1,000 per patient annually